Skip to content

Independent register of U.S. FDA drug recalls · updated Oct 10, 2026

FDA Drug Recalls

18,003 recalls, newest first

Mar 23, 2023 Class II · Moderate risk

Clopidogrel Tablets USP

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-8190-9 D-0513-2023

Mar 23, 2023 Class II · Moderate risk

Atorvastatin Calcium Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-7631-9 D-0512-2023

Mar 23, 2023 Class II · Moderate risk

Atorvastatin Calcium Tablets

cGMP Deviations for the manufacturing Firm (Accord Healthcare) after their inspection.

Ongoing cGMP deviation Preferred Pharmaceuticals, Inc. NDC 68788-7630-9 D-0511-2023

Mar 22, 2023 Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-121-60 D-0509-2023

Mar 22, 2023 Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-213-30 D-0508-2023

Mar 22, 2023 Class II · Moderate risk

Alprazolam C-IV

CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.

Ongoing Cross-contamination Direct Rx NDC 72189-0240-30 D-0507-2023

Mar 20, 2023 Class II · Moderate risk

Simvastatin 40 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-0060-01 D-0503-2023

Mar 20, 2023 Class II · Moderate risk

Rosuvastatin 40mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-1311-01 D-0502-2023

Mar 20, 2023 Class II · Moderate risk

Rosuvastatin 10mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-0375-03 D-0501-2023

Mar 20, 2023 Class II · Moderate risk

Rosuvastatin 5mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-3519-00 D-0500-2023

Mar 20, 2023 Class II · Moderate risk

Ropinirole 2mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-2750-00 D-0499-2023

Mar 20, 2023 Class II · Moderate risk

Atorvastatin 20 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-1977-00 D-0498-2023

Mar 20, 2023 Class II · Moderate risk

Tadalafil 5 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-2972-00 D-0497-2023

Mar 20, 2023 Class II · Moderate risk

Simvastatin 10 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-0064-01 D-0496-2023

Mar 20, 2023 Class II · Moderate risk

Rosuvastatin 5mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-3519-00 D-0495-2023

Mar 20, 2023 Class II · Moderate risk

Ropinirole 0.5 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-2439-00 D-0494-2023

Mar 20, 2023 Class II · Moderate risk

Glimepiride 2 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-0405-03 D-0493-2023

Mar 20, 2023 Class II · Moderate risk

Doxazosin 2 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-1560-00 D-0492-2023

Mar 20, 2023 Class II · Moderate risk

Atorvastatin 10 mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-1946-00 D-0491-2023

Mar 20, 2023 Class II · Moderate risk

Aripiprazole 5mg tablets

cGMP Deviations

Terminated cGMP deviation RemedyRepack Inc. NDC 70518-2921-03 D-0490-2023

Mar 17, 2023 Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-179-00 D-0759-2023

Mar 17, 2023 Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-178-00 D-0758-2023

Mar 17, 2023 Class II · Moderate risk

Glimepiride Tablets

CGMP Deviations: recalling drug products following an FDA inspection.

Terminated cGMP deviation Amerisource Health Services LLC NDC 68001-177-00 D-0757-2023

Mar 17, 2023 Class II · Moderate risk

Aripiprazole Tablets

Out of specification (OOS) for Spectroscopic Identification test by IR.

Ongoing Failed specification Ascend Laboratories, LLC D-0539-2023

Mar 16, 2023 Class II · Moderate risk

Tadalafil Tablets

CGMP Deviations

Ongoing cGMP deviation Northwind Pharmaceuticals LLC NDC 51655-487-52 D-0554-2023

Recalls by year

2026563
2025778
2024557
20231,122
20221,390
20211,152
2020930
20191,788
20181,681
20171,141
20161,199
20151,733
20141,309
20132,085
2012534
201134
20104
20072
20061